Insitro has raised no outside funding. Biotech company. The last valuation is $2.4B, dated Sep 2021.
Insitro is backed by investors including Lowercarbon Capital, Khosla Ventures and Baillie Gifford, which fund its combination of automated cellular experiments and population-scale genetics to bring better medicines to patients faster.
Insitro was founded in 2013, United States.
Biotech company. The company is valued at $2.4B , dated Sep 2021.
No longer independent.
Biotech company.
Last valuation$2.4BSep 2021
Lowercarbon Capital
Khosla Ventures
Baillie Gifford
Redpoint Ventures
Founders FundThe routes section explains what is realistically available for a company at this stage.
No. Insitro was acquired by CombinAble.AI Biotech firm combining automated cellular experiments and population genetics with AI to identify disease drivers and deliver targeted therapeutics; its shares do not trade independently.
The last valuation is $2.4B.
Lead investors for each round are in the funding timeline.
The closest biotechnology peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
